CATALYST PHARMACEUTICALS, INC.
About CATALYST PHARMACEUTICALS, INC.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $589.0M
- Net income
- $214.3M
- Total assets
- $1.1B
- Market cap
- $3.8B
- Gross margin
- 85.2%
- Operating margin
- 43.8%
- Net margin
- 36.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $589.0M
- Cost of revenue
- $87.3M
- Gross profit
- $501.7M
- Operating expenses
- $206.5M
- Operating income
- $257.8M
- Income tax
- $69.2M
- Net income
- $214.3M
- EPS (basic)
- $1.75
- EPS (diluted)
- $1.68
Balance sheet
- Total assets
- $1.1B
- Current assets
- $894.0M
- Total liabilities
- $149.7M
- Current liabilities
- $147.2M
- Shareholders’ equity
- $954.3M
Cash flow
- Operating cash flow
- $208.7M
- Investing cash flow
- -$58.0K
- Financing cash flow
- -$17.0M
- Net cash flow
- $191.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.8B
- P/E ratio
- 18.6
- EPS (diluted)
- $1.68
- Shares outstanding
- 122.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 8, 2006
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $214.3M in FY2025.
- Revenue grew 318% from FY2021 to FY2025.
- Gross margin of 85.2%, net margin 36.4%.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 18.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CATALYST PHARMACEUTICALS, INC..
Write a review
News about CATALYST PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
